Compare ICG & MIRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ICG | MIRA |
|---|---|---|
| Founded | 2017 | 2020 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.4M | 43.7M |
| IPO Year | 2022 | 2023 |
| Metric | ICG | MIRA |
|---|---|---|
| Price | $0.92 | $0.92 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $5.25 | N/A |
| AVG Volume (30 Days) | ★ 69.2K | 67.9K |
| Earning Date | 05-21-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.60 | $0.90 |
| 52 Week High | $3.22 | $2.45 |
| Indicator | ICG | MIRA |
|---|---|---|
| Relative Strength Index (RSI) | 55.07 | 41.63 |
| Support Level | $0.63 | N/A |
| Resistance Level | $1.36 | $1.01 |
| Average True Range (ATR) | 0.09 | 0.05 |
| MACD | 0.04 | -0.00 |
| Stochastic Oscillator | 79.39 | 8.87 |
Intchains Group Ltd is an inventive altcoins development company that engages in the provision of altcoin mining products, the strategic acquisition and holding of Ethereum-based cryptocurrencies and the active development of inventive Web3 applications. The company offers high-performance mining products including altcoin mining machines incorporating its ASIC chips that have high computing power and superior power efficiency, ASIC chips and ancillary software and hardware, all of which cater to the evolving needs of the blockchain industry. Geographically, it operates in Mainland China, Hong Kong, and Other countries or regions.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.